Sequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasms.

Oncotarget · 2017 · PMC5464878 · PMID 28422716

Europe PMC DOI

hedged sentence

0.0610

closest p · 1.2× alpha

0.0610

boldest claim

The sentences

showed a trendP = 0.061so close (0.05 < p ≤ 0.1)

Multivariate analysis to evaluate the effect of mutation ( CALR vs JAK2 ) on the slope of mutant burden in not treated pts with a positive slope adjusting for diagnosis (ET vs PMF) showed a trend toward a higher increase of mutant burden in CALR vs JAK2 (β = 0.19, P = 0.061) with no difference between diagnosis ( P = 0.419).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.